J Manag Care Spec Pharm. 2022 Jan;28(1):125-131. doi: 10.18553/jmcp.2021.21217. Epub 2021 Oct 1.
As part of its stand against racial injustice and its commitment to action, AMCP dedicated a partnership forum to discussion of potential sources of racial health disparities and inequities in benefit design because these are primary drivers of medication use. This forum, held virtually March 23-24, 2021, convened more than 40 experts representing key stakeholders from managed care settings. Key principles that emerged from the forum discussion as means to mitigate racial health disparities were to acknowledge that structural racism exists and that it can impact the provision of health care, including but not limited to formulary development and benefit design processes; to integrate proactive strategies to improve equity, beginning with education and training, into all aspects of health care; and to view patients holistically with an understanding of the compounding effect of social determinants of health on their personal wellness. With these principles in mind, participants highlighted several priority considerations including improving existing gaps in data, addressing diversity and equity as they relate to formulary development, evaluating systems such as benefit offerings through a lens of increasing equity, recognizing cost-related factors that affect equity, considering patients' interactions with and their ability to access the system, and committing to patient-centered care. Participants also suggested areas for policy-related focus and noted the need to develop and deploy specific education and training. This forum was sponsored by Amgen, the National Pharmaceutical Council, Pfizer, PhRMA, Sandoz, and Takeda. Their representatives joined the forum as panelists or participants. These proceedings were prepared as a summary of the forum to represent common themes; they are not necessarily endorsed by all attendees nor should they be construed as reflecting group consensus.
作为其反对种族不公正和承诺采取行动的一部分，AMCP 专门设立了一个合作论坛，讨论潜在的种族健康差异和福利设计中的不平等的根源，因为这些是药物使用的主要驱动因素。该论坛于 2021 年 3 月 23 日至 24 日以虚拟形式举行，召集了来自管理式医疗环境的 40 多名代表主要利益相关方的专家。论坛讨论中出现的缓解种族健康差异的关键原则包括承认结构性种族主义的存在，以及它可能影响医疗保健的提供，包括但不限于处方集开发和福利设计流程；将积极主动的战略纳入医疗保健的各个方面，以改善公平，从教育和培训开始；以及从整体上看待患者，了解健康决定因素对他们个人健康的综合影响。考虑到这些原则，与会者强调了几个优先考虑的事项，包括缩小现有数据差距，解决与处方集开发相关的多样性和公平问题，通过增加公平性的视角评估福利等系统，认识到影响公平的与成本相关的因素，考虑患者与系统的互动及其获取系统的能力，并致力于以患者为中心的护理。与会者还提出了政策相关重点领域，并指出需要制定和部署具体的教育和培训。本次论坛由安进、国家药品理事会、辉瑞、PhRMA、山德士和武田赞助。他们的代表作为小组成员或参与者参加了论坛。这些记录是作为论坛的总结编写的，以代表共同的主题；它们不一定得到所有与会者的认可，也不应被解释为反映小组共识。
